32% DUPIXENT Surge Shields Legacy Drag: Aggressive R&D Expansion Accelerates (REGN Q4 2025 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Regeneron relies on massive DUPIXENT growth to aggressively fund an unprecedented expansion of its clinical pipeline, even as its legacy ophthalmology franchise navigates intense competitive headwinds. The company is actively shifting its focus toward a heavily investment-focused 2026, signaling a willingness to compress near-term margins to secure a wave of next-generation blockbuster assets.
Massive DUPIXENT Revenue Bolsters Stable Cash Flow
Regeneron reported a 3% year-over-year increase in fourth-quarter total revenue, largely sustained by its immunology juggernaut. Global net sales for DUPIXENT spiked 32% on a constant currency basis to $4.9 billion, while oncology asset LIBTAYO advanced 13% globally to $425 million. In contrast, U.S. net sales for legacy EYLEA 2 milligrams dropped 15% sequentially to $577 million amidst a tightening anti-VEGF market. The company ended 2025 generating $4.1 billion in free cash flow and returned $3.8 billion to shareholders, predominantly through stock repurchases.
Unprecedented R&D Investment Points Toward 18 New Phase III Trials
Management outlined a heavily investment-focused 2026, targeting R&D expenses between $5.9 billion and $6.1 billion as the company prepares to initiate 18 new Phase III studies involving roughly 35,000 patients. Chief Financial Officer Chris Fenimore noted gross margins on net product sales are projected between 83% and 84%, reflecting a shifting product mix alongside bulk manufacturing scale-up costs. CEO Leonard Schleifer stressed that they anticipate at least four FDA approvals over the next year, setting the foundation for the company's next wave of product launches.
EYLEA HD Achieves 18% Net Sales Growth Amid Category Contraction
The ophthalmology segment navigated a complicated landscape, with EYLEA HD reaching $506 million in fourth-quarter U.S. net sales, marking an 18% sequential increase. Commercial chief Marion McCourt explicitly attributed this performance to a 10% sequential bump in physician demand, despite the broader anti-VEGF category declining 7% sequentially. On the immunology front, DUPIXENT solidified its dominance with more than 1.4 million patients globally, while multiple myeloma treatment Lynozyfic demonstrated remarkable monotherapy activity in late-line settings by showing complete response rates nearly double those of competing bispecifics.
Strategic Focus on Dual-Action Obesity Combo Over Pure Weight Loss
Analysts pressed executives on their strategy within the highly competitive obesity landscape. Management revealed a differentiated approach, co-formulating a GLP/GIP agonist with a PCSK9 antibody in a single auto-injector to simultaneously treat obesity and reduce LDL cholesterol by 50% to 60%. Addressing the ophthalmology pipeline, Chief Scientific Officer George Yancopoulos clarified that their systemic complement inhibitors targeting geographic atrophy aim to eliminate the dangerous side effects associated with current intravitreal treatments. Additionally, executives hinted at a next-generation molecule entering clinical development to potentially improve upon DUPIXENT's durability.